Document is current
Any future updates will be listed below
-
Authors
Fulford, Thomas S. https://orcid.org/0000-0002-7210-5739
Soliman, Caroline
Castle, Rebecca G.
Rigau, Marc https://orcid.org/0000-0001-5978-1073
Ruan, Zheng
Dolezal, Olan
Seneviratna, Rebecca
Brown, Hamish G.
Hanssen, Eric
Hammet, Andrew
Li, Shihan
Redmond, Samuel J.
Chung, Amy https://orcid.org/0000-0003-0020-9704
Gorman, Michael A.
Parker, Michael W. https://orcid.org/0000-0002-3101-1138
Patel, Onisha
Peat, Thomas S.
Newman, Janet
Behren, Andreas https://orcid.org/0000-0001-5329-280X
Gherardin, Nicholas A. https://orcid.org/0000-0003-4690-2571
Godfrey, Dale I. https://orcid.org/0000-0002-3009-5472
Uldrich, Adam P. https://orcid.org/0000-0002-6350-5976
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1184906, 1165467, 1117766, 2008913, 1194263)
Cancer Council Victoria (1126866)
Department of Education and Training | Australian Research Council (DP230102753, CE140100011, DE210100705)
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 11 June 2024
First Online: 16 July 2024
Competing interests
: A.H. is an employee of CSL Limited and can partake in employee share schemes. A.B. and A.H. are inventors on a patent regarding the use of BTN2A1 to influence immune reactions (WO2015077844). T.S.F., M.R., A.H., A.B., D.I.G. and A.P.U. are inventors on a patent regarding methods of inhibiting or activating γδ T cells (WO2020257871). A.P.U., D.I.G., T.S.F., N.A.G. and M.R. are inventors on filed patents regarding BTN-mediated activation of γδ T cells. The other authors declare no competing interests.
